Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.

Hypertension
Rhonda M Cooper-DeHoffJulie A Johnson

Abstract

We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg of hydrochlorothiazide or 100 mg of atenolol monotherapy followed by their combination. Fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, and uric acid levels were measured at baseline and after monotherapy and combination therapy. Outcomes included new occurrence of and predictors for new cases of glucose > or =100 mg/dL (impaired fasting glucose), triglyceride > or =150 mg/dL, high-density lipoprotein < or =40 mg/dL for men or < or =50 mg/dL for women, or new-onset diabetes mellitus according to the presence or absence of abdominal obesity. Abdominal obesity was present in 167 (58%) of 395 patients. Regardless of strategy, in those with abdominal obesity, 20% had impaired fasting glucose at baseline compared with 40% at the end of study (P<0.0001). Proportion with triglycerides > or =150 mg/dL increased from 33% at baseline to 46% at the end of study (P<0.01). New-onset diabetes melli...Continue Reading

Associated Clinical Trials

References

Feb 12, 2002·American Journal of Epidemiology·A Colin BellBarry M Popkin
Dec 18, 2003·The American Journal of Medicine·James R Sowers
May 27, 2004·Diabetes Care·Tara M WallaceDavid R Matthews
Oct 16, 2004·American Journal of Hypertension·Peter BramlageArya M Sharma
Jan 18, 2005·Annals of Epidemiology·Daniel L McGee, UNKNOWN Diverse Populations Collaboration
Jan 22, 2005·American Heart Journal·Gilles R DagenaisSalim Yusuf
Apr 6, 2006·JAMA : the Journal of the American Medical Association·Cynthia L OgdenKatherine M Flegal
Apr 25, 2006·Journal of the American College of Cardiology·Javed ButlerUNKNOWN Health ABC Study
Jun 15, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Rhoda H CobinUNKNOWN AACE Menopause Guidelines Revision Task Force
Apr 26, 2008·American Journal of Hypertension·Michael H Alderman
May 27, 2008·The American Journal of Medicine·Gregory A NicholsJonathan B Brown
Jun 14, 2008·The Journal of Clinical Hypertension·Lydia Sebba Souza MariosaMaria Teresa Zanella
Jun 20, 2008·Diabetes, Obesity & Metabolism·George BakrisUNKNOWN STAR Investigators
Jul 2, 2008·Diabetes Care·Earl S FordNaveed Sattar
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Rhonda M Cooper-DeHoff
Dec 4, 2008·International Journal of Obesity : Journal of the International Association for the Study of Obesity·H GhandehariN D Wong
Jul 3, 2009·Clinical Pharmacology and Therapeutics·J A JohnsonJ G Gums
Jul 1, 2008·Journal of the American Society of Hypertension : JASH·Melvin R Hayden, James R Sowers

❮ Previous
Next ❯

Citations

Nov 4, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Graziela Z Kalil, William G Haynes
Jun 10, 2010·Current Hypertension Reports·Pieter M JansenAnton H van den Meiracker
May 26, 2010·Journal of Hypertension·James R SowersPrakash C Deedwania
Mar 4, 2014·Endocrinology and Metabolism Clinics of North America·Guido LastraJames R Sowers
Dec 13, 2012·Optometry : Journal of the American Optometric Association·Samantha L C NogalesHuey-Fen Song
Oct 7, 2015·Clinical Pharmacology and Therapeutics·U AnyanwaguRichard Donnelly
Apr 27, 2012·The Journal of Clinical Hypertension·Barry L Carter
May 18, 2010·Biochemical and Biophysical Research Communications·Xiaodong ZhangHeyao Wang
Jun 8, 2015·Current Opinion in Cardiology·Wanpen Vongpatanasin
Feb 11, 2015·Metabolic Syndrome and Related Disorders·Liming WengRhonda M Cooper-DeHoff
Oct 3, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Jie PengWei Zhang
Dec 17, 2010·World Journal of Cardiology·Steven G Chrysant
Apr 19, 2013·Hypertension·James R Sowers
Jun 12, 2013·Journal of the American Heart Association·Rhonda M Cooper--DeHoffAlmut G Winterstein
Mar 15, 2014·Circulation. Cardiovascular Genetics·Rhonda M Cooper-DehoffJulie A Johnson
Jun 10, 2010·Expert Review of Cardiovascular Therapy·Julio D Duarte, Rhonda M Cooper-DeHoff
Jul 16, 2020·Menopause : the Journal of the North American Menopause Society·Fatima Cody StanfordJoAnn E Manson
Feb 26, 2021·The Journal of Clinical Hypertension·Jian-Feng HuangUNKNOWN HOPE Asia Network

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Postgraduate Medicine
Xavier Pi-Sunyer
Trends in Endocrinology and Metabolism : TEM
M L ReitmanS I Taylor
Drug Discovery Today
Andrea R Nawrocki, Philipp E Scherer
Best Practice & Research. Clinical Endocrinology & Metabolism
Wieland KiessJürgen Kratzsch
© 2022 Meta ULC. All rights reserved